CS
GLUE icon

Candriam SCA’s Monte Rosa Therapeutics GLUE Stock Holding History

Candriam SCA’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-135,000
Closed -$763K – 710
2023
Q4 		$763K Hold
135,000
– – 0.01% 622
2023
Q3 		$647K Hold
135,000
– – ﹤0.01% 604
2023
Q2 		$925K Buy
+135,000
New +$873K 0.01% 611

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Candriam SCA's GLUE Position: Q1 2024 in Review

Candriam SCA sold out of Monte Rosa Therapeutics (GLUE) in Q1 2024, closing a stake of 135,000 shares — an estimated $763K sold.

Candriam SCA first reported a position in GLUE in Q2 2023 and held it in 3 quarters. The position peaked at $925K in Q2 2023. 68 funds tracked by Wall St. Rank hold GLUE as of Q1 2024.

  • Candriam SCA reported no remaining Monte Rosa Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Candriam SCA sold 135,000 Monte Rosa Therapeutics shares in Q1 2024, an estimated $763K.
  • Candriam SCA first reported a position in Monte Rosa Therapeutics in Q2 2023 and held it in 3 quarters.
  • Candriam SCA's Monte Rosa Therapeutics position peaked at $925K in Q2 2023.
  • 68 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2024.

Based on Candriam SCA's 13F filing for Q1 2024, filed 6 May 2024.